Floatz logo

exs73565

Marginal Zone Lymphoma (MZL)

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

105 Active assets in the Marginal Zone Lymphoma (MZL) cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

exs73565 is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
diffuse large B-cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →